What Is the Maximum Dose of Vyvanse in 24 Hours?

The maximum FDA-approved dose of Vyvanse (lisdexamfetamine dimesylate) is 70 mg taken once per day, for both ADHD and binge eating disorder. There is no approved scenario in which a second dose is added later in the day to reach a higher total. That 70 mg ceiling exists not because of an arbitrary regulatory cutoff but because of how the drug is built: Vyvanse is a prodrug, and the body can only convert it into its active form so fast, which creates a natural pharmacological speed limit that shapes everything about its dosing.

Why the Ceiling Is 70 mg

Vyvanse is not active when you swallow it. The capsule contains lisdexamfetamine, which is d-amphetamine bonded to the amino acid lysine. Your body has to cleave off that lysine before d-amphetamine is released. This cleavage happens primarily inside red blood cells, where peptidase enzymes do the work.¹ The conversion is not instant. Red blood cells process the prodrug at a relatively steady pace, which means that even if you take a very large amount, the rate at which active d-amphetamine enters your bloodstream does not spike the way it would with an immediate-release stimulant.

Research on this conversion process confirmed that the transport of lisdexamfetamine across the red blood cell membrane is not the bottleneck; the enzymatic hydrolysis itself governs the pace.² This rate-limited conversion is what makes Vyvanse’s blood levels rise and fall in a smooth, predictable curve rather than a sharp peak and crash. At therapeutic doses of 30 to 70 mg, the drug follows a linear, dose-proportional pharmacokinetic profile, meaning doubling the dose roughly doubles the drug exposure in a proportional way.³ The clinical trials that established efficacy tested 30, 50, and 70 mg doses and found all three produced significant improvement in ADHD symptoms. Going above 70 mg was never shown to add meaningful benefit, so the FDA drew the line there.

How Long a Single Dose Stays Active

One reason there is no need for a second daily dose is that Vyvanse lasts a long time. After you take it, d-amphetamine levels in your blood typically peak around three to four and a half hours later.⁴ From there, the active drug clears slowly. The half-life of d-amphetamine released from Vyvanse has been measured at roughly 10 to 17 hours depending on the study and the population, meaning it takes that long for the blood concentration to drop by half.⁵ In practice, most people experience symptom coverage for about 10 to 14 hours from a single morning dose.

That long tail is also why taking a second dose within 24 hours is discouraged. If you took 70 mg in the morning and another 70 mg eight hours later, the second dose would start releasing d-amphetamine while a substantial amount from the first dose was still circulating. The overlap could push total d-amphetamine exposure well beyond what clinical trials evaluated, increasing the risk of cardiovascular strain, insomnia, and other adverse effects without any evidence that it improves symptom control.

When the Maximum Is Lower Than 70 mg

For some people, 70 mg is not the safe upper limit. Your kidneys play a major role in clearing both the intact prodrug and d-amphetamine from your body. When kidney function is reduced, the drug hangs around longer and reaches higher peak concentrations. A dedicated pharmacokinetic study found that people with severe kidney impairment should be capped at 50 mg per day, and those with end-stage renal disease should not exceed 30 mg per day.⁶ If you have chronic kidney disease or are on dialysis, the standard 70 mg maximum does not apply to you, and your prescriber should be adjusting accordingly.

Children also have their own dosing pathway. Vyvanse is approved for ADHD in children ages six and up, and the recommended starting dose is 30 mg per day, titrated upward in 10 or 20 mg increments. The maximum approved dose for pediatric patients is the same 70 mg per day, but clinicians are more cautious about reaching that ceiling because children are more sensitive to cardiovascular changes. In one study of children starting Vyvanse, a small number of stimulant-naïve subjects experienced tachycardia or blood pressure readings outside normal range, with one child showing a prolonged QTc interval on an electrocardiogram that resolved at follow-up.⁷ Events like these are why pediatric dose escalation typically proceeds slowly, with monitoring at each step.

Drug Interactions That Quietly Raise Your Effective Dose

Even if you take exactly 70 mg per day, certain medications can make your body behave as though you took more. After Vyvanse is converted to d-amphetamine, a portion of that d-amphetamine is further metabolized by the liver enzyme CYP2D6. If you take another drug that inhibits CYP2D6, d-amphetamine clearance slows down, and blood levels rise. A review of drug interactions in ADHD treatment noted that clinicians should be aware of this effect because CYP2D6 inhibitors can increase amphetamine levels, which is functionally equivalent to increasing the dose.⁸

Common CYP2D6 inhibitors include certain antidepressants like fluoxetine (Prozac), paroxetine (Paxil), and bupropion (Wellbutrin), along with some antihistamines and antipsychotics. If you are taking any of these alongside Vyvanse, your effective amphetamine exposure could be meaningfully higher than what the milligram number on your capsule suggests. This does not necessarily mean you need to lower your Vyvanse dose, but it is something your prescriber should be factoring in, especially if you start noticing side effects like a faster resting heart rate or trouble sleeping that were not present before adding the interacting drug.

Cardiovascular Effects at Therapeutic Doses

Stimulant medications raise blood pressure and heart rate. With Vyvanse, a systematic review of safety data found small average increases in blood pressure and pulse rate across patients taking the drug at approved doses.⁹ For most healthy people, these increases are clinically insignificant, on the order of a few beats per minute and a few millimeters of mercury. But “small average increases” conceal a wide range of individual responses. Some people see no cardiovascular change at all; others experience meaningful jumps, particularly at higher doses or when combined with caffeine, decongestants, or the CYP2D6 inhibitors discussed above.

If you have pre-existing hypertension, a structural heart condition, or an arrhythmia, the risk calculus changes considerably. The prescribing information for Vyvanse includes warnings against use in patients with serious structural cardiac abnormalities or other conditions where sympathomimetic stimulation could be dangerous. Taking more than the prescribed dose magnifies these cardiovascular risks in a dose-dependent way, and that is one of the core reasons the ceiling exists where it does.

Psychiatric Risks Climb With Dose

The cardiovascular story is relatively well known, but the psychiatric risks of higher amphetamine exposure are underappreciated. A large case-control study found that people with recent prescription amphetamine use had roughly 2.7 times the odds of experiencing psychosis or mania compared to non-users. More strikingly, the risk followed a clear dose-response pattern: at doses above 30 mg of dextroamphetamine equivalents, the odds of psychosis or mania jumped to about five times higher than baseline.¹⁰

Because Vyvanse 70 mg delivers approximately 21 mg of d-amphetamine (the conversion ratio is roughly 0.2948 mg of d-amphetamine per mg of lisdexamfetamine), a single 70 mg dose stays below that 30 mg threshold. But exceeding the prescribed dose, or stacking doses within 24 hours, could push you into the higher-risk zone. This is especially relevant for people with a personal or family history of bipolar disorder, psychotic episodes, or schizophrenia. The symptoms of stimulant-induced psychosis, including paranoia, auditory hallucinations, and agitated confusion, can be frightening and may require emergency treatment. They are also sometimes misdiagnosed as a primary psychiatric condition rather than a drug effect, leading to inappropriate long-term treatment.

What Overdose Actually Looks Like

Poison center data provides a window into what happens when people take more Vyvanse than prescribed. A comparison of stimulant exposures reported to U.S. poison centers found that the most common effects of lisdexamfetamine overdose were agitation (about 20% of cases) and tachycardia (about 19%). The majority of reported exposures, roughly three-quarters, resulted in no effects or only minor effects. More serious outcomes occurred in about 21% of lisdexamfetamine cases, which was slightly lower than rates seen with immediate-release amphetamine formulations.¹¹

The relatively lower rate of serious outcomes with Vyvanse compared to immediate-release amphetamines likely reflects the prodrug design. Even in overdose, the body can only convert lisdexamfetamine to d-amphetamine at a limited rate, which means the peak blood level of active drug rises more gradually than it would with an equivalent overdose of instant-release amphetamine. That does not make Vyvanse overdose safe. Serious complications of amphetamine toxicity include dangerously high body temperature, seizures, rhabdomyolysis (muscle breakdown that can damage the kidneys), cardiac arrhythmias, and in rare cases, death. But the prodrug mechanism provides a partial buffer that does not exist with other formulations.

Tolerance and the Temptation to Escalate

One of the most common reasons people consider exceeding their prescribed dose is that it stops working as well as it used to. Tolerance to stimulant medications is a real phenomenon with a biological basis. Animal studies have shown that chronic stimulant use can lead to changes in dopamine signaling, including increased dopamine transporter density and heightened sensitivity of autoreceptors that dial down dopamine release.¹² Research on methylphenidate (a related but different stimulant) demonstrated that a flat dosing pattern lost about 40% of its afternoon efficacy compared to the same blood level in the morning, suggesting acute tolerance within a single day.

When people notice their afternoon focus waning, the instinct is often to add a booster dose or to request a higher prescription. But the evidence on tolerance points to biological adaptation rather than an insufficient amount of drug in the blood, and simply adding more milligrams does not reliably fix the problem. Strategies that clinicians use instead include drug holidays (brief periods off the medication to let receptor sensitivity reset), switching formulations, adjusting the timing of the dose, or adding a non-stimulant adjunct medication. Self-escalating beyond 70 mg per day is one of the riskier paths a person can take, because it compounds cardiovascular and psychiatric risks while the tolerance mechanism continues to adapt upward in lockstep.

The Prodrug Design and Abuse Deterrence

The 70 mg ceiling also intersects with Vyvanse’s design as an abuse-deterrent formulation. A review of preclinical and clinical literature on Vyvanse’s abuse potential found that compared to immediate-release dextroamphetamine, lisdexamfetamine generally produced a delayed onset of effects and a lower peak concentration, which was associated with a diminished feeling of euphoria.¹³ Epidemiological studies found that real-world abuse rates of lisdexamfetamine were substantially lower than those of immediate-release dextroamphetamine.

That said, the review also noted that not all data pointed in the same direction. Some researchers reported similar peak concentrations between lisdexamfetamine and dextroamphetamine at certain doses, and the drug still had reinforcing properties that increased with dose. In other words, the prodrug design makes abuse harder and less rewarding than crushing up an immediate-release tablet, but it does not make it impossible. Taking supratherapeutic doses of Vyvanse will still produce euphoria, cardiovascular strain, and the other effects of high-dose amphetamine, it just takes more pills to get there and the onset is slower. The rate-limiting conversion is a speed bump, not a wall.

Urine pH and Individual Variation in Clearance

How quickly your body eliminates d-amphetamine is not fixed. One underappreciated variable is urine pH. Amphetamines are weak bases, and in acidic urine, more of the drug becomes ionized and gets trapped in the kidney tubules for excretion rather than being reabsorbed back into the blood. In alkaline urine, the opposite happens: more d-amphetamine is reabsorbed, effectively prolonging its action and raising its blood levels. This means that dietary factors, supplements, or medications that shift urine pH can meaningfully alter how long d-amphetamine stays in your system.

Vitamin C supplements and acidic beverages can accelerate clearance, potentially shortening the drug’s effective duration. Conversely, sodium bicarbonate (baking soda), certain antacids, and diets heavy in vegetables and fruits that alkalinize urine can slow excretion and boost exposure. These are not dramatic overnight changes, but over time, or in combination with other factors like CYP2D6 inhibition or renal impairment, they can meaningfully shift where a given milligram dose lands in terms of actual drug exposure. Two people taking the same 70 mg capsule can end up with meaningfully different d-amphetamine blood levels based on nothing more than their kidney function, liver enzyme activity, and what they had for breakfast.

Why Prescribers Sometimes Prescribe Below the Maximum

The existence of a 70 mg maximum does not mean everyone should be on 70 mg. Clinical practice guidelines for ADHD treatment emphasize starting low and titrating to the minimum effective dose, not to the maximum tolerated dose. Many adults do well on 30 or 50 mg per day, and there is no evidence that higher doses produce better long-term outcomes for everyone. The dose-response curve for symptom improvement tends to flatten out at a certain point while the dose-response curve for side effects keeps climbing. Finding the right dose means balancing symptom control against side effects like appetite suppression, insomnia, elevated heart rate, and mood changes.

For binge eating disorder, the same 70 mg ceiling applies, and the titration typically proceeds from 30 mg upward in weekly increments. The clinical trials for this indication tested the same dose range as the ADHD trials. As with ADHD, the goal is not to reach the maximum but to find the dose that adequately reduces binge episodes without unacceptable side effects. If 50 mg controls binge eating and 70 mg gives you insomnia and jaw clenching, 50 mg is the right dose regardless of what the label allows.